TIGIT and malignant epithelioid mesothelioma: Our study presents evidence of the potent synergy achieved through the combination of anti-PD-1 and anti-TIGIT antibodies, leading to a remarkable 90% response rate, complete tumour rejection, and the establishment of enduring tumour immunity, in this mouse model of epithelioid mesothelioma.